Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UCD-186 | |||
| UCD-200614601 | |||
| CDR0000583066 | Other Identifier | UC Davis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods.
Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Metastatic Breast Cancer | Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy |
| |
| Non-cancer medical illness | Patients with non-cancer medical condition |
| |
| Healthy Controls | Healthy patients being seen for an annual exam |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Healthy Controls | Other | One blood draw (2 teaspoons) |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness | up to 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Predictability of serial serum biomarkers in determining disease response and/or progression | Up to 18 months |
Not provided
DISEASE CHARACTERISTICS:
Patient or participant at the Women's Health Clinic, the Internal Medicine Clinic, or at the UC Davis Cancer Center, meeting 1 of the following criteria:
Diagnosis of stage IV metastatic breast cancer, receiving active treatment with chemotherapy, endocrine therapy, or targeted therapy
Patients/participants without cancer
Healthy control being seen for annual exams, meeting the following criteria:
Patient without cancer being seen in the Internal Medicine Clinic
Hormone receptor status not specified
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Patients with metastatic breast cancer receiving active chemotherapy, endocrine therapy or targeted therapy Healthy age matched controls without chronic diseases and not on regular prescription medications Patients seen at Internal Medicine Clinic for any reason other than active, metastatic cancer
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen K. Chew, MD | University of California, Davis | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California Davis Cancer Center | Sacramento | California | 95817 | United States |
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Metastatic Breast Cancer |
| Other |
Blood samples will be drawn every 3 months, for up to 18 months. |
|
| Non-cancer medical illness | Other | One blood draw (2 teaspoons) |
|
| D017437 |
| Skin and Connective Tissue Diseases |